Successful Desensitization Treatment with Osimertinib after the Development of Osimertinib-induced Urticaria in a Patient Undergoing Treatment for Non-small Cell Lung Cancer Harboring the EGFR T790M Mutation

被引：4
|
作者：
Makimoto, Go [1 ]
Nishi, Tatsuya [1 ]
Kawakado, Keita [1 ]
Nishimura, Tomoka [1 ]
Tamura, Tomoki [1 ]
Kudo, Kenichiro [1 ]
Kuyama, Shoichi [1 ]
机构：
[1] Natl Hosp Org Iwakuni Clin Ctr, Dept Resp Med, Iwakuni, Yamaguchi, Japan
来源：
INTERNAL MEDICINE | 2020年 / 59卷 / 17期
关键词：
osimertinib; desensitization; non-small-cell lung cancer; epidermal growth factor receptor; SUCCESSFUL ORAL DESENSITIZATION; HYPERSENSITIVITY REACTIONS; ACQUIRED-RESISTANCE; GENE-MUTATIONS; OPEN-LABEL; GEFITINIB; CHEMOTHERAPY; INHIBITORS; TKI;
D O I：
10.2169/internalmedicine.4429-20
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Some patients discontinue receiving osimertinib for non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) Thr790Met (T790M) mutation due to adverse its effects. We report a case of successful desensitization therapy after osimertinib-induced urticaria. An 85-year-old Japanese woman received osimertinib as third-line therapy for NSCLC with the EGFR T790M mutation. After two days, she developed urticaria of the lower extremities. We started osimertinib desensitization therapy at 0.1 mg/day, which was gradually increased to 40 mg/day. She continued osimertinib for >12 months without adverse effects. Desensitization therapy with osimertinib could be useful for patients experiencing osimertinib-induced urticaria.
引用
收藏
页码：2161 / 2164
页数：4
相关论文
共 50 条
  • [1] Mixed Response of Non-Small Cell Lung Cancer Harboring the EGFR T790M Mutation to Osimertinib
    Shinno, Y.
    Goto, Y.
    Sato, J.
    Morita, R.
    Matsumoto, Y.
    Murakami, S.
    Kanda, S.
    Horinouchi, H.
    Fujiwara, Y.
    Yamamoto, N.
    Ohe, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2145 - S2145
  • [2] Osimertinib for the Treatment of Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
    Khozin, Sean
    Weinstock, Chana
    Blumenthal, Gideon M.
    Cheng, Joyce
    He, Kun
    Zhuang, Luning
    Zhao, Hong
    Charlab, Rosane
    Fan, Ingrid
    Keegan, Patricia
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2017, 23 (09) : 2131 - 2135
  • [3] Osimertinib-induced Stevens-Johnson syndrome in a patient with EGFR T790M mutation-positive non-small cell lung cancer
    Lin, Yi-Tsz
    Chu, Chia-Yu
    LUNG CANCER, 2019, 129 : 110 - 111
  • [4] Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer
    Soejima, Kenzo
    Yasuda, Hiroyuki
    Hirano, Toshiyuki
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (01) : 31 - 38
  • [5] EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
    Zheng, Qiufan
    Hong, Shaodong
    Huang, Yan
    Zhao, Hongyun
    Yang, Yunpeng
    Hou, Xue
    Zhao, Yuanyuan
    Ma, Yuxiang
    Zhou, Ting
    Zhang, Yaxiong
    Fang, Wenfeng
    Zhang, Li
    CLINICAL AND TRANSLATIONAL MEDICINE, 2020, 9 (01):
  • [6] The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer
    Gao, Xin
    Le, Xiuning
    Costa, Daniel B.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (04) : 383 - 390
  • [7] Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
    Skoulidis, Ferdinandos
    Papadimitrakopoulou, Vassiliki A.
    CLINICAL CANCER RESEARCH, 2017, 23 (03) : 618 - 622
  • [8] Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
    Nobuaki Mamesaya
    Hirotsugu Kenmotsu
    Toshiaki Takahashi
    Investigational New Drugs, 2017, 35 : 839 - 841
  • [9] Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
    Mamesaya, Nobuaki
    Kenmotsu, Hirotsugu
    Takahashi, Toshiaki
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (06) : 839 - 841
  • [10] Clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of EGFR+ non-small cell lung cancer without the T790M mutation
    Hu, Xueyang
    Chen, Wenjun
    Li, Xiaoqiu
    Zhao, Chenchen
    Zhang, Congjun
    Xiong, Fuxing
    Wu, Hongyang
    ANNALS OF PALLIATIVE MEDICINE, 2019, 8 (05) : 525 - 531
12345